Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02009397
Title A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors James Graham Brown Cancer Center
Indications

melanoma

Therapies

Sargramostim

Ipilimumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.